At advanced stages, we demonstrate that the combined AD-like Aβ and tau transgenic expression resulted in increased amyloidosis and tauopathy as compared to that of the transgenic version of single pathologies, and, likewise, more marked cognitive impairments. The gene discussed is MAPT; the disease is amyloidosis.